10/18/2024

Janusmed sex and gender

Janusmed sex and gender – colchicine

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Colchicine

Colchicine

Class : C

Show all info

Print

Contact us

  1. Mikuls TR. Gout. N Engl J Med. 2022;387(20):1877-1887.

  2. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380-390.

  3. Colrefuz (colchicine). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2023-02-20, cited 2024-04-25]

  4. Colcrys (colchicine). DailyMed [www]. U.S National Library of Medicine. [updated 2023-12-29, cited 2024-04-25].

  5. Dogruer D, Tug E, Bes C, Soy M. Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of Familial Mediterranean fever. Genet Mol Res. 2013;12(3):3521-8.

  6. Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum. 2004;33(4):273-82.

  7. Chu CC, Chen YC, Lin MH, Wu WT, Liu FC, Chen HC et al. Association between Clinical Use of Colchicine and Risk of Type 2 Diabetes Mellitus among Gouty Patients: A Nationwide Cohort Study. Int J Environ Res Public Health. 2022;19(6):.

  8. Satiş H, Armağan B, Bodakçi E, Ataş N, Sari A, Yaşar Bilge NŞ et al. Colchicine intolerance in FMF patients and primary obstacles for optimal dosing. Turk J Med Sci. 2020;50(5):1337-1343.

  9. Todd BA, Billups SJ, Delate T, Canty KE, Kauffman AB, Rawlings JE et al. Assessment of the association between colchicine therapy and serious adverse events. Pharmacotherapy. 2012;32(11):974-80.

  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. Mikuls TR. Gout. N Engl J Med. 2022;387(20):1877-1887.
  2. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380-390.
  3. Colrefuz (colchicine). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2023-02-20, cited 2024-04-25]
  4. Colcrys (colchicine). DailyMed [www]. U.S National Library of Medicine. [updated 2023-12-29, cited 2024-04-25].
  5. Dogruer D, Tug E, Bes C, Soy M. Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of Familial Mediterranean fever. Genet Mol Res. 2013;12(3):3521-8.
  6. Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum. 2004;33(4):273-82.
  7. Chu CC, Chen YC, Lin MH, Wu WT, Liu FC, Chen HC et al. Association between Clinical Use of Colchicine and Risk of Type 2 Diabetes Mellitus among Gouty Patients: A Nationwide Cohort Study. Int J Environ Res Public Health. 2022;19(6):.
  8. Satiş H, Armağan B, Bodakçi E, Ataş N, Sari A, Yaşar Bilge NŞ et al. Colchicine intolerance in FMF patients and primary obstacles for optimal dosing. Turk J Med Sci. 2020;50(5):1337-1343.
  9. Todd BA, Billups SJ, Delate T, Canty KE, Kauffman AB, Rawlings JE et al. Assessment of the association between colchicine therapy and serious adverse events. Pharmacotherapy. 2012;32(11):974-80.
  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]